Evidence map›Paper›PMID 26843851›Full record

ArticleBiological procedures online2016

Lambda Red-mediated Recombineering in the Attaching and Effacing Pathogen Escherichia albertii.

Marisa Egan, Jasmine Ramirez, Christian Xander, Chirag Upreti, Shantanu Bhatt

Open access · goldAbstract read
In one paragraph

Article in Biological procedures online, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. First report ofASM case reports · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Microbiology and Epidemiology ofMicroorganisms · 2022
    Review
  12. Article
  13. Lambda Red-Mediated Recombination in Shiga Toxin-Producing Escherichia coli.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marisa EganDepartment of Biology, Saint Joseph's University, 5600 City Avenue, Philadelphia, PA 19131 USA ; Department of Mathematics, Saint Joseph's University, 5600 City Avenue, Philadelphia, PA 19131 USA.
Jasmine RamirezDepartment of Biology, Saint Joseph's University, 5600 City Avenue, Philadelphia, PA 19131 USA ; Present address: Microbiology Department, Perelman School of Medicine, University of Pennsylvania, 3610 Hamilton Walk, 221 Johnson Pavilion, Philadelphia, PA 19104 USA.
Christian XanderDepartment of Biology, Saint Joseph's University, 5600 City Avenue, Philadelphia, PA 19131 USA ; Present address: Bluemle Life Sciences Building, Thomas Jefferson University, 233 South Tenth Street, Philadelphia, PA 19107 USA.
Chirag UpretiHoward Hughes Medical Institute, Columbia University Medical Center, Columbia, USA ; Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032 USA.
Shantanu BhattDepartment of Biology, Saint Joseph's University, 5600 City Avenue, Philadelphia, PA 19131 USA.
Saint Joseph's University · USColumbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ability to introduce site-specific mutations in bacterial pathogens is essential towards understanding their molecular mechanisms of pathogenicity. This has been greatly facilitated by the genetic engineering technique of recombineering. In recombineering, linear double- or single-stranded DNA molecules with two terminal homology arms are electroporated into hyperrecombinogenic bacteria that express a phage-encoded recombinase. The recombinase catalyzes the replacement of the endogenous allele with the exogenous allele to generate selectable or screenable recombinants. In particular, lambda red recombinase has been instrumental in engineering mutations to characterize the virulence arsenal of the attaching and effacing (A/E) pathogens enteropathogenic Escherichia coli (EPEC), enterohemorrhagic E. coli (EHEC), and Citrobacter rodentium. Escherichia albertii is another member of this taxon; however, the virulence of E. albertii remains cryptic despite accumulating evidence that E. albertii is an emerging pathogen. Multiple retrospective studies have reported that a substantial number of EPEC and EHEC isolates (~15 %) that were previously incriminated in human outbreaks actually belong to the E. albertii lineage. Thus, there is increased urgency to reliably identify and rapidly engineer mutations in E. albertii to systematically characterize its virulence determinants. To the best of our knowledge not a single chromosomal gene has been altered by targeted mutagenesis in E. albertii since it was first isolated almost 25 years ago. This is disconcerting because an E. albertii outbreak could cause significant morbidity and mortality owing to our inadequate understanding of its virulence program.

resultsIn this report we describe a modified lambda red recombineering protocol to mutagenize E. albertii. As proof of principle, we successfully deleted three distinct virulence-associated genetic loci - ler, grlRA, and hfq - and replaced each wild type allele by a mutant allele with an encodable drug resistance cassette bracketed by FRT sites. Subsequently, the FRT-site flanked drug resistance marker was evicted by FLP-dependent site-specific recombination to generate excisants containing a solitary FRT site.

conclusionsOur protocol will enable researchers to construct marked and unmarked genome-wide mutations in E. albertii, which, in turn, will illuminate its molecular mechanisms of pathogenicity and aid in developing appropriate preventative and therapeutic approaches to combat E. albertii outbreaks.

Indexed as

BetEscherichia albertiiExoGamLEERecombineering

Identifiers

PMID26843851
PMCPMC4739404
OpenAlexW2258043929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.